Somapacitan
Pre-clinicalRecruiting 1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency in Children
Conditions
Growth Hormone Deficiency in Children
Trial Timeline
Oct 4, 2023 → Jul 31, 2026
NCT ID
NCT06109935About Somapacitan
Somapacitan is a pre-clinical stage product being developed by Novo Nordisk for Growth Hormone Deficiency in Children. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06109935. Target conditions include Growth Hormone Deficiency in Children.
What happened to similar drugs?
11 of 20 similar drugs in Growth Hormone Deficiency in Children were approved
Approved (11) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06709040 | Pre-clinical | Recruiting |
| NCT06109935 | Pre-clinical | Recruiting |
| NCT05718570 | Pre-clinical | Recruiting |
| NCT05723835 | Phase 3 | Active |
| NCT05230550 | Pre-clinical | Recruiting |
| NCT03905850 | Phase 1 | Completed |
| NCT03212131 | Phase 1 | Completed |
| NCT03186495 | Phase 1 | Completed |
| NCT02962440 | Phase 1 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency in Children